HIV Infections Clinical Trial
Official title:
ART Adherence: Enhanced Counseling and Observed Therapy
This study will compare the effectiveness of enhanced counseling alone versus enhanced counseling combined with observed therapy at improving medication adherence in people with HIV.
HIV is a virus that can lead to acquired immunodeficiency syndrome (AIDS), a disease that
breaks down the immune system and allows for entry of life-threatening secondary infections.
HIV is transmitted through the exchange of bodily fluids, primarily through sexual
intercourse. Antiretroviral therapy (ART) has proven to be an effective treatment for
inhibiting the replication of HIV, allowing for improved quality of life and survival.
However, the long-term effectiveness of ART depends on strict adherence to a prescribed
medication regimen. Previous studies have indicated that observing patients while they take
their medications for a period of time can improve adherence to their prescribed drug
regimens. This study will evaluate the effectiveness of enhanced counseling (EC) alone
versus EC combined with modified directly observed therapy (mDOT) at improving medication
adherence in people with HIV.
Participants in this 48-week study will be randomly placed into one of the following three
treatment groups:
- Group 1 participants will receive standard care, which will involve the care that the
clinic staff normally provide to all patients on HIV therapy.
- Group 2 participants will receive EC.
- Group 3 participants will receive EC with mDOT.
All participants will continue to take the anti-HIV medication regimen prescribed by their
health care provider. However, participants will be asked to keep one medication type in a
bottle that has a special Micro-Electro-Mechanical System (MEMS) cap. This electronic cap
will record each time the participant opens the bottle. Participants will meet with study
staff for MEMS cap data collection once weekly for the first 4 weeks, every 2 weeks up to
Week 12, and then every 4 weeks thereafter.
EC will consist of 30- to 45-minute counseling sessions about medication adherence.
Participants will meet in person with a counselor for the first five sessions, occurring at
baseline and Weeks, 1, 2, 6, and 11. An additional five counseling sessions will be
conducted by phone during Weeks 4, 9, 15, 19, and 23. Participants receiving mDOT will have
their doses of HIV medication delivered to them by an mDOT worker for the first 24 weeks of
treatment. Participants will select a time and location to meet with an mDOT staff member,
who will then provide the daily doses of drugs and observe participants taking those drugs.
Participants will meet with an mDOT worker 5 times a week from baseline to Week 16. Starting
at Week 17, the number of weekly meetings will gradually taper until Week 24 when there will
be no meeting and participants will return to obtaining and taking their HIV medications as
done prior to study enrollment.
Evaluation visits will occur for all participants at baseline and Weeks 12, 24, 36, and 48.
Evaluation sessions will last 45 minutes to 1 hour and will include questionnaires about
adherence, knowledge and attitudes about HIV and HIV therapy, quality of life, support
systems, health status, medical history, drug and alcohol use, and satisfaction with HIV
care. Blood samples will also be taken to measure CD4 cell count and amount of virus in the
blood.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |